Half-year report · Q2
4530.TEDINET S100UIMD
Period2024-03-01 → 2024-08-31
Filed2024-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥75.5bn | 2024-03-01 → 2024-08-31 | Cons. | Net sales |
| Revenue | ¥141.7bn | 2023-03-01 → 2024-02-29 | Cons. | Net sales (5-year summary) |
| Revenue | ¥67.0bn | 2023-03-01 → 2023-08-31 | Cons. | Net sales |
| Operating income | ¥9.0bn | 2024-03-01 → 2024-08-31 | Cons. | Operating income |
| Operating income | ¥8.4bn | 2023-03-01 → 2023-08-31 | Cons. | Operating income |
| Ordinary income | ¥10.8bn | 2024-03-01 → 2024-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥19.6bn | 2023-03-01 → 2024-02-29 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.6bn | 2023-03-01 → 2023-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥13.1bn | 2024-03-01 → 2024-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥11.6bn | 2023-03-01 → 2023-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥9.1bn | 2024-03-01 → 2024-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.0bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥8.4bn | 2023-03-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥9.4bn | 2024-03-01 → 2024-08-31 | Cons. | Profit loss |
| Net income | ¥8.7bn | 2023-03-01 → 2023-08-31 | Cons. | Profit loss |
| Total assets | ¥350.5bn | at 2024-08-31 | Cons. | Assets |
| Total assets | ¥328.8bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥344.3bn | at 2023-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥74.5bn | at 2024-08-31 | Cons. | Liabilities |
| Total liabilities | ¥61.7bn | at 2024-02-29 | Cons. | Liabilities |
| Net assets / equity | ¥275.9bn | at 2024-08-31 | Cons. | Net assets |
| Net assets / equity | ¥267.1bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥275.1bn | at 2023-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥113.6bn | at 2024-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥112.5bn | at 2024-02-29 | Cons. | Cash and deposits |
| Cash & equivalents | ¥68.6bn | at 2024-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥66.4bn | at 2024-02-29 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥81.2bn | at 2023-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥65.4bn | at 2023-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥8.3bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥18.2bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7.9bn | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥4.2bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.5bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥10.4bn | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥12.3bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥16.7bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.8bn | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥122.71 | 2024-03-01 → 2024-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥181.62 | 2023-03-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.34 | 2023-03-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥122.55 | 2024-03-01 → 2024-08-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥181.42 | 2023-03-01 → 2024-02-29 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥108.23 | 2023-03-01 → 2023-08-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 78.0% | at 2024-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.5% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.2% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 462
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment | Prior1YTDDuration | Original text (Japanese)当社の報告セグメントは「医薬品事業」のみであるため、記載を省略しています。 | |
| Description of fact that companys business comprises single segment | CurrentYTDDuration | Original text (Japanese)当社の報告セグメントは「医薬品事業」のみであるため、記載を省略しています。 | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |